UK Interdisciplinary Breast Cancer Symposium

Programme

19 - 20 January 2026
ICC Birmingham

UKIBCS is partially funded by our Conference Sponsors. These companies had no input in the meeting agenda, choice of speakers, or arrangements of this Symposium. With the exception of their individual industry-sponsored symposia.

UK Interdisciplinary Breast Cancer Symposium

Programme - Monday 19 January 2026

8:00AM - 8:45AM	**Registration, exhibition and posters viewing**			
8:45AM - 9:00AM	**Welcome and introduction** Andreas Makris - Chair of UKIBCS **Hall 1**			
9:00AM - 10:00AM	**Updates of the Year** Chair: Andreas Makris **Early breast cancer** Catherine Harper-Wynne - Maidstone and Tunbridge Wells NHS Trust, Kent, UK **Metastatic breast cancer** Alicia Okines - Royal Marsden NHS Foundation Trust, London, UK **Translational research** Leonie Young - Royal College of Surgeons in Ireland, Dublin, Ireland **Hall 1**			
10:00AM - 10:30AM	**Plenary 1 - Does anyone still need a mastectomy?** Anna Weiss - University of Rochester Medical Center, New York, USA Introduced by Stuart Mcintosh - Queen's University Belfast, UK **Hall 1**			
10:30AM - 11:00AM	**Morning refreshment break, exhibition & poster viewing**			
Parallel Session 1 11:00AM - 12:15PM	**1.1 Personalising breast cancer surgery** Chairs: Sarah Downey & Stuart McIntosh **Personalising risk-reducing surgery for women at high risk of breast cancer** Marjanka Schmidt - Netherlands Cancer Institute, Amsterdam, Netherlands **Personalising breast and axillary surgery in 2026** Henry Cain - Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK **Do all patients with ER+ disease need radiotherapy and endocrine therapy?** Icro Meattini - University of Florence, Italy **Hall 1**	**1.2 ER-Low: What is it and what are the therapeutic implications?** Chairs: Mitch Dowsett & Sarah Pinder **ER low invasive breast cancer – what it is?** Sarah Pinder - Kings College London, UK **ER-low biology and endocrine sensitivity** Mitch Dowsett - Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, UK **Should we treat ER-low as triple negative or as ER+ve?** Andrew Tutt - Guy's Hospital & Institute of Cancer Research, London, UK **Hall 11**	**1.3 Tumour immunology and Immunotherapy** Chairs: Ingunn Holen & Val Speirs **Modelling the inflammatory microenvironment associated with obesity** Stephen Beers - University of Southampton, UK **Unveiling Myeloid Cell Plasticity in Early Breast Cancer Metastasis** Luigi Ombrato - Queen Mary University of London, UK **Optimising breast cancer immunotherapy whilst limiting treatment-driven adverse events** Awen Gallimore - Cardiff University, UK **Hall 10**	**1.4 Managing the gaps in care with healthcare professional and organisational collaborations** Chairs: Sally Kum & Claire Ryan **Last year of life, unscheduled care. Acute oncology and supportive care: a multi provider perspective** Declan Cawley - East Kent Hospitals, UK **"Like falling off the edge of a cliff": How to manage the gaps after adjuvant treatment in primary breast cancer** Juanita Caseley - Maidstone & Tunbridge Wells NHS Trust, UK **Myths and misinformation in social media** Dan Papworth-Smyth - Breast Cancer Now **Hall 9**
12:15PM - 1:40PM	**Lunch, exhibition & poster viewing**			

Sponsored Symposia 12:30PM - 1:30PM	**Sponsored Symposium:** **Exact Sciences - Emerging relationship of genomic assays, hereditary cancer risk, and CDK4/6 inhibition in current clinical practice for EBC** Mark Verrill - Consultant Medical Oncologist, Newcastle upon Tyne Hospitals Foundation NHS Trust, UK Mark Harries - Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust, UK Sarah Downey - Consultant Surgeon (Breast), James Paget University Hospitals NHS Foundation Trust, UK Caroline Wilson - Consultant in Medical Oncology, The Christie NHS Foundation Trust, UK **Hall 11**	**Sponsored Symposium:** **Novartis - Broadening treatment horizons: Advancing care in HR+/ HER2- Breast Cancer** Iain McPherson - Professor of Breast Oncology, University of Glasgow and Honorary Consultant in Medical Oncology, Beatson West of Scotland Cancer Centre, UK Vipin Kuriakose - Clinical Oncologist Consultant, Russells Hall and New Cross Hospitals, UK Suzanne Frank - Advanced Specialist Breast Cancer Pharmacist, The Christie NHS Foundation Trust, UK Fharat Raja - Consultant Medical Oncologist, University College London Hospitals NHS Foundation Trust / Royal Free Hospital, UK **Hall 9**	**Sponsored Symposium:** **MSD - From diagnosis to decisions: Identifying and managing eligible patients for treatment in early-stage triple-negative breast cancer (TNBC)** Henry Cain - Consultant Surgeon, Newcastle Upon Tyne Hospitals NHS Trust, UK Catherine Harper-Wynne - Consultant Medical Oncologist, Kent Oncology Centre - Maidstone, UK **Hall 10**	
1:40PM - 2:10PM	**Plenary 2 - Cridlan Lecture: Genetics update** Judy Garber - Dana-Farber Cancer Institute & Harvard Medical School, Massachusetts, USA Introduced by Gillian Ross, Royal Marsden NHS Foundation Trust, London, UK **Hall 1**			
Parallel Session 2 2:20PM - 3:35PM	**2.1 Genomic testing in breast cancer: germline panels, incidental findings and the PARTNER trial** Chairs: Diana Eccles & Ellen Copson **Germline testing in breast cancer patients: which genes and why?** Helen Hanson - Royal Devon University NHS Foundation Trust/ University of Exeter Medical School, Exeter, UK **ctDNA testing in breast cancer: interpretation of results and managing the unexpected findings** Terri McVeigh - Royal Marsden NHS Foundation Trust, London, UK **The PARTNER Trial - Strategies to identify the optimal treatments in early-stage triple negative breast cancer** Jean Abraham - University of Cambridge, UK **Hall 1**	**2.2 Breast radiotherapy – challenges and opportunities of complex treatments** Chairs: Charlotte Coles & Anna Kirby **How do we combine radiotherapy and targetted therapies optimally** Icro Meattini - University of Florence, Italy **Who should have regional radiotherapy and what is benefit?** Charlotte Coles - University of Cambridge, UK **Proton beam therapy – what have we learnt from the trials so far?** Anna Kirby - Royal Marsden NHS Foundation Trust, London, UK **Hall 11**	**2.3 Transforming breast cancer research and management with AI** **Chairs: Gerald Lip & Sarah Vinnicombe** **The evolving role of AI in breast pathology** Anita Grigoriadis - King's College London, UK **Digital health & PROs in breast cancer care** Ines Vaz Luis - Gustave Roussy, Paris, France **Generative AI and LLM in education and training** Gerald Lip - NHS Grampian, Aberdeen, UK **Hall 9**	**2.4 Abstracts from future leaders** Chairs: Ingunn Holen & Ramsey Cutress **Black Women's Decisions about Breast Cancer Screening in the UK: From Evidence to Community Impact** Anietie Aliu - University of Surrey, UK **Needs of people with triple negative breast cancer (TNBC): The Patient's Voice** Hira Yousuf - St James's University Hospital, Leeds, UK **Does Personalised Stratified Follow-Up (PSFU) meet the needs of people from under-served groups who have completed treatment for breast cancer? (The B-POISED study)** Katie Sutton - University of Surrey, UK **Who's Doing What?: Multidisciplinary team perspectives on delivering Self-Directed Aftercare following breast cancer** Anna Isaac - Queen's University Belfast, UK **Digital spatial profiling of male breast cancer** Luca Foley - University of Aberdeen, UK **The Clinical and Molecular Landscape of Breast Cancer in Women of African and South Asian Ancestry** Graeme Thorn - Queen Mary University of London, UK **Evaluation of staff time and material costs to introduce Trastuzumab Deruxtecan as treatment for metastatic HR+ HER2-low Breast Cancer compared to Paclitaxel** Francesco Abbadessa - Kent and Medway Medical School, UK **Hall 10**

3:35PM - 4:05PM	Afternoon refreshment break, exhibition & poster viewing			
Parallel Session 3 4:05PM - 5:20PM	**3.1 Does the MDT know what it's doing?** Chairs: Sarah Downey & Leena Chagla **Would I receive better care at a different Trust?** Kieran Horgan - Leeds Teaching Hospitals, UK **Can good care or poor care be reflected in numbers and rates?** Sarah Downey - James Paget University Hospitals NHS Foundation Trust, Norfolk, UK **Comparing breast cancer outcomes globally: strengths and limitations of existing data** Toral Gathani - Nuffield Department of Population Health, University of Oxford, UK **Hall 11**	**3.2 Practical issues related to young women and breast cancer** Chairs: Anne Armstrong & Judy King **Management of breast cancer during pregnancy** Anne Armstrong - Christie Hospital, Manchester, UK **Determining menopausal status in women with early breast cancer** Ephia Yasmin - University College London Hospitals NHS Foundation Trust, UK **HRT after a diagnosis of breast cancer** Rebecca Bowen - Royal United Hospitals Bath NHS Foundation Trust, Bath, UK **Hall 1**	**3.3 Treating the whole person: Understanding Integrative Oncology** Chairs: Lesley Turner & Claire Ryan **What is Integrative Oncology? Debunking the myths, correcting the narrative** Penny Kechagioglou - University Hospitals Coventry and Warwickshire NHS Trust, UK **Optimisation of diet and supplements for patients living with and beyond breast cancer** Nina Fuller-Shavel - National Centre for Integrative Oncology, Reading, UK **Science & Synergy: Truths and tools in integrative oncology** Lauren Watts - NHS England, London, UK **Hall 10**	**3.4 UK Clinical trials** Chairs: Stuart McIntosh & Judith Bliss **Supporting researcher development in clinical trials** Anna Kirby - Royal Marsden NHS Foundation Trust, London, UK **Focus on current/new UK clinical trials** **a. HER2-RADiCAL** Iain MacPherson - University of Glasgow, UK **b. FAST-FORWARD BOOST** Carmel Anandadas - The Christie NHS Foundation Trust, Manchester, UK **c. TADPOLE** Shelley Potter - University of Bristol, UK **d. OPTIMA-YOUNG** Ines Vaz Luis - Gustave Roussy, Paris, France **Enhancing trials using routine data linkage** Lucy Kilburn - The Institute of Cancer Research, UK **Panel discussion** **Mairead MacKenzie - Independent Cancer Patients' Voice (ICPV), UK** Lisa Crane - Patient Advocate, UK **Hall 9**
5:20PM - 5:25PM	Transition to Plenary			
5:25PM - 6:00PM	**Plenary 3 - The NHS now and in the future** Richard Meddings CBE - Immediate past-Chair of NHS England and Chair-elect of Breast Cancer Now Chair: Claire Rowney - CEO, Breast Cancer Now **Hall 1**			
6:00PM - 7:30PM	Drinks reception & poster viewing			

Programme - Tuesday 20 January 2026

8:15AM - 9:00AM	Registration Poster viewing and exhibition in Hall 3			
9:00AM - 9:30AM	**Plenary 4 - Implementation of AI in screening** Fredrik Strand - Karolinska Institute, Solna, Sweden Introduced by Gerald Lip - President of British Society of Breast Radiology (BSBR) **Hall 1**			
9:30AM - 9:45AM	Transition to Parallel Session 4			
Parallel Session 4 9:45AM - 11:00AM	**4.1 Minimally invasive treatment** Chairs: Sarah Pinder & Stuart McIntosh **Do all small low-risk breast cancers have to be removed?** Stuart Mcintosh - Queen's University Belfast, UK **Tailoring axillary surgery in the upfront setting** Shelley Potter - University of Bristol, UK **How low should you go – neoadjuvant systemic therapy in small EBCs?** Iain MacPherson - University of Glasgow, UK **Hall 11**	**4.2 Towards personalisation of screening** Chairs: Sarah Vinnicombe & Gerald Lip **AI in image based risk assessment** Fredrik Strand - Karolinska Institute, Solna, Sweden **Density based screening: MyPeBS and BRAID** Fiona Gilbert - University of Cambridge, UK **Digital breast tomosynthesis (DBT) for breast cancer screening** Keshthra Satchithanda - King's College Hospital, London, UK **Hall 1**	**4.3 Implementation of lifestyle interventions** Chairs: Caroline Wilson & John Saxton **Implementing lifestyle interventions in early breast cancer** Carol Keen - Active Together Cancer Rehabilitation, Sheffield, UK **Implementing lifestyle interventions in metastatic breast cancer** Lucy Gossage - Nottingham University Hospitals NHS Trust, UK **The NEWDAY study – a bespoke lifestyle intervention after primary treatment for early breast cancer** John Saxton - University of Hull, UK **Integrating physical activity into standard of care after breast cancer** Sam Orange - Newcastle University, UK **Hall 10**	**4.4 Recent advances in ER+ HER2- metastatic breast cancer** Chairs: Stephen Johnston & David Miles **Recent progress with SERDs according to ESR1 genotype; where to next?** Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK **Clinical experience with PI3K/AKT inhibitors** Olga Oikonomidou - University of Edinburgh, UK **The role of mutation testing in the treatment and sequencing of the treatment of ER+ HER2- metastatic breast cancer** Richard Baird - Cancer Research UK Cambridge Centre/University of Cambridge, UK **Hall 9**
11:00AM - 11:30AM	Morning refreshment break, exhibition & poster viewing			

Parallel Session 5 11:30AM - 12:45PM	**5.1 Dormancy/late relapse** Chairs: Mitch Dowsett & Angela DeMichele **Relationship of tumour phenotype with time to recurrence** Mitch Dowsett - Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, UK **A gene therapy approach to preventing outgrowth of dormant breast cancer cells in bone** Penny Ottewell - University of Sheffield, UK **The emerging role of ctDNA in early detection and treatment of late metastases** Nick Turner - Royal Marsden NHS Foundation Trust, London, UK **Hall 1**	**5.2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Update** Chairs: David Dodwell & Jeremy Braybrooke **Introduction to EBCTCG and its methods** Robert Hills - University of Oxford, UK **EBCTCG meta-analyses – what, how, and why?** Richard Berry & Graham Beake -University of Oxford, UK **Recent results – Axillary management, Ovarian suppression, Extended endocrine therapy** David Dodwell - University of Oxford, UK & Jeremy Braybrooke - University Hospitals Bristol NHS Foundation Trust, UK **Trying to further progress of personalised breast cancer care in EBCTCG** Robert Hills - University of Oxford, UK **Hall 9**	**5.3 Introduction of new systemic treatments: Antibody-drug conjugates** Chairs: Michal Sladkowski & Catherine Harper-Wynne **Mode of Action** Neil Masters - Sheffield Teaching Hospitals NHS Foundation Trust, UK **Clinical applications and toxicity** Andrew Proctor - York and Scarborough Teaching Hospitals NHS Foundation Trust, UK **Novel forms of drug delivery; ADCs and beyond** Jenny Hiscock - University of Kent, UK **Hall 11**	**5.4 Abstracts from future leaders** Chairs: Ellen Copson & Henry Cain **Treatment delivery and clinical outcomes from a pilot regional systemic anti-cancer therapy (SACT) clinic for early HER2-positive breast cancer** Santiago Teran - The Christie NHS Foundation Trust, Manchester, UK **Do brands matter? Insights from the SWITCH study on healthcare professionals' perceptions of oral SACT brand changes** Rebecca Todd - University College London, UK **Using carcinoma-associated fibroblasts as a model to investigate biological differences between male and female breast cancer** Fiona Saunders - University of Aberdeen, UK **Risk of second cancers after hypofractionated radiotherapy among breast cancer survivors in England** Imogen Sawyer - The Institute of Cancer Research, UK **Developing a Rotational Breast CNS Trainee Programme: Building the Future Specialist Nursing Workforce** Esther Kershaw - Maidstone and Tunbridge Wells NHS Trust, UK **Deep Learning Based Breast Lesion Segmentation from Ultrasound in Young Women** Vivek Singh - Barts Cancer Institute, Queen Mary University of London, UK **Expression of VEGF-C in stromal cells in primary breast cancer improves clinical nodal prediction models supporting omission of sentinel node biopsy** Lisa Rydén - Lund University, Sweden **Hall 10**
12:45PM - 2:10PM	**Lunch, exhibition & poster viewing**			

Sponsored Symposia 1:00PM - 2:00PM	**Sponsored Symposium: Eli Lilly - Does one size fit all in EBC?** Chair: Mark Beresford - Royal United Hospital Bath Stephen Johnston - Royal Marsden Hospital, UK Racha Kussaibati - University Hospitals Birmingham, UK **Hall 10**	**Sponsored Symposium: AstraZeneca - Targeting therapy in HER2-negative aBC: guided by genomics** Chair: Ellen Copson - Professor and Honorary Consultant in Medical Oncology at the University of Southampton, UK Nick Turner - Professor of Molecular Oncology and Honorary Consultant in Medical Oncology at the Institute of Cancer Research & The Royal Marsden, UK George Burghel - Consultant Clinical Scientist, Manchester University NHS Foundation Trust, UK **Hall 11**	**Sponsored Symposium: Gilead - Building Trust Through Communication Between Health Care Professionals and Patients Living with Metastatic triple negative breast cancer (mTNBC)** Caroline Michie - Consultant Medical Oncologist, Honorary Clinical Senior Lecturer at the Edinburgh Cancer Centre and the University of Edinburgh Mukesh B Mukesh - Consultant Clinical Oncologist, East Suffolk & North Essex NHS Trust Lesley Fallowfield - Professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex **Hall 9**
2:00PM - 2:10PM	**Transition to Prizes & Plenary 5**		
2:10PM - 2:20PM	**Prizes for abstracts by future leaders** **Hall 1**		
2:20PM - 2:50PM	**Plenary 5 - Dormancy decoded: Strategies to eradicate minimal residual disease** Angela DeMichele - University of Pennsylvania, Philadelphia, USA Introduced by Mitch Dowsett - Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, UK **Hall 1**		
2:50PM - 3:00PM	**Transition to Parallel Session 6**		
Parallel Session 6 3:00PM - 4:15PM	**6.1 Progress in supporting patients with metastatic breast cancer** Chairs: Carlo Palmieri & Lesley Stephen **Secondary breast cancer summit and patient experience of research** Carlo Palmieri - University of Liverpool, UK & Lesley Stephen - Make 2nds Count, UK **Management of oligometastases in 2026** Mark Beresford - Royal United Hospital Bath, UK **Local therapy for brain metastases** Sara Meade - University Hospitals Birmingham NHS Foundation Trust, UK **Hall 1**	**6.2 Communication: harnessing new technology** Chairs: Lesley Fallowfield & David Dodwell **Managing anger in the breast clinic: a VR training programme** Val Shilling - University of Sussex, Brighton, UK **You, me and the bot makes 3: influence of AI on consultations** Richard Simcock - Macmillan Cancer Support, Brighton, UK **Are remote consultations our new normal?** Lesley Fallowfield - University of Sussex, Brighton, UK **Hall 11**	**6.3 What to do when a diagnosis of breast cancer collides with existing health disparities** Chairs: Susannah Stanway & Charlotte Coles **Challenges of delivering quality, comprehensive breast cancer care in LMICs and solutions** Miriam Mutebi - Aga Khan University Hospital, Nairobi, Kenya **Cancer inequities and unique breast cancer healthcare needs for LGBTIAQ+ community** Alison Berner - Queen Mary University of London, UK **Breast cancer inequities related to race & ethnicity & complex interplay between (epi)genetics & structural racism** Olubukola Ayodele - University Hospitals of Leicester NHS Trust, UK **Hall 9**
	Close of the Symposium		

The information contained in this programme was accurate at the time of printing; however, all speakers, timings, and content are subject to change.

Notes

The information contained in this programme was accurate at the time of printing; however, all speakers, timings, and content are subject to change.